Physician profile
David E Scott
NPI 1609874536
$4,142.30
in general payments reported to CMS, 2019-2025
16 companies · $135 in 2025
The $135 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,082 · 2020: $103 · 2021: $447 · 2022: $729 · 2023: $323 · 2024: $325 · 2025: $135.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $782.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $782.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $1,804.96 | 2019-2021 | |
| Alcon Vision LLC | $991.11 | 2019-2025 | Rocklatan, Rhopressa, Simbrinza |
| Johnson & Johnson Vision Care, INC. | $400.85 | 2019-2024 | Acuvue |
| Coopervision INC. | $213.96 | 2019-2022 | |
| Tarsus Pharmaceuticals, INC. | $135.77 | 2024-2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $134.47 | 2023 | Infuse, Vyzulta, Lotemax Sm |
| Oyster Point Pharma, INC. | $121.61 | 2022 | |
| Horizon Therapeutics Plc | $107.77 | 2023 | Tepezza |
| Allergan, INC. | $43.22 | 2020-2021 | |
| Alcon Research LLC | $41.97 | 2019 | |
| Novartis Pharmaceuticals Corporation | $36.31 | 2021-2022 | |
| Astellas Pharma US INC | $35.09 | 2024 | Izervay |
| Shire North American Group INC | $34.17 | 2019 | |
| Aerie Pharmaceuticals, INC. | $19.56 | 2019 | |
| Maculogix, INC. | $12.33 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Quidel Corporation | $9.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Scott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.